Mary Pat Lancelotta is currently the Senior Vice President of the MRD BioPharma business at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Mary Pat brings over 20 years of commercial and strategy experience in life sciences and diagnostics with a focus in oncology, and she has held leadership roles in both start-ups and Fortune 500 companies. She previously served as Vice President Strategic Marketing at Foundation Medicine where she launched FoundationOne and FoundationOne Heme, and also led strategic communications through several rounds of financing, including the IPO and acquisition by Roche. She came to FMI from Quest Diagnostics where she led commercial strategic planning for the company’s $5B laboratory services business and served as chief-of-staff to the Chief Medical Officer. Earlier in her career, Mary Pat spent seven years in consulting with Accenture and The Frankel Group, a boutique life sciences consulting firm. She has been a strategic consultant to several early stage oncology/early detection diagnostic companies. Additionally, she serves or has served on the board of directors for two private companies, Molecular Match and Ultivue, as well as Target Cancer Foundation, a non-profit advancing clinical research for rare cancers. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry, magna cum laude, from Boston College.